Ani Pharmaceuticals (ANIP) Cost of Revenue (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Cost of Revenue data on file, last reported at $93.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 28.13% year-over-year to $93.6 million; the trailing twelve-month figure through Mar 2026 stood at $361.9 million (up 32.02% YoY), and the FY2025 full-year result was $341.3 million, up 36.41% from the prior year.
• Cost of Revenue retreated to $93.6 million in Q1 2026, from $100.3 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $100.3 million in Q4 2025 to a low of $32.9 million in Q3 2022.
• A 5-year average of $59.1 million and a median of $53.4 million in 2023 frame the typical range for Cost of Revenue.
• Peak annual rise in Cost of Revenue reached 71.48% in 2022, while the deepest fall reached 7.16% in 2022.
• Tracing ANIP's Cost of Revenue over 5 years: stood at $36.3 million in 2022, then jumped by 47.06% to $53.4 million in 2023, then soared by 50.28% to $80.3 million in 2024, then gained by 24.9% to $100.3 million in 2025, then declined by 6.67% to $93.6 million in 2026.
• Business Quant data shows ANIP's Cost of Revenue at $93.6 million in Q1 2026, $100.3 million in Q4 2025, and $93.4 million in Q3 2025.